
 Rapid tests PIONER 5 in 1 for the determination of sulfonamides, tylosin, tilmicosin, lincomycin, erythromycin, fluoroquinolones
Rapid tests PIONER 5 in 1 for the determination of sulfonamides, tylosin, tilmicosin, lincomycin, erythromycin, fluoroquinolones PIONEER MEIZHENG BIO-TECH (5 in1) JC0871/ Rapid tests for the determination of the residual amount of β-lactams, tetracyclines, chloramphenicol, streptomycins, ceftiofur in milk, whey.
PIONEER MEIZHENG BIO-TECH (5 in1) JC0871/ Rapid tests for the determination of the residual amount of β-lactams, tetracyclines, chloramphenicol, streptomycins, ceftiofur in milk, whey.The Novosibirsk Center for Virology and Biotechnology Vector plans to apply for approval of the EpiVacCoron CORONAVIRUS vaccine to the World HEALTH Organization (WHO). However, this task is not a top priority, said Rinat Maksyutov, DIRECTOR of the Center.
Vector plans to apply for vaccine approval to the WHO. But this is directly linked to the issue of vaccine exports. And now for us it is a priority to meet domestic demand, to protect the population of the Russian Federation. Therefore, at present, this issue is not so relevant, ”TASS quoted Maksyutov as saying.
He added that now Vector has more than a hundred applications from abroad from various countries and organizations with requests for the supply of a vaccine or technology transfer. According to Maksyutov, the demand for EpiVacKorona remains very high.
The EpiVacCorona coronavirus vaccine was registered on October 13, 2020. The drug became the second Russian vaccine against covid-19 . Clinical trials of the drug began in early December. The vaccine entered civilian circulation on January 1, 2021.
"EpiVacCoron" was created on the basis of artificially synthesized short fragments of viral proteins. With their help, the immunity of a vaccinated person must learn to recognize virus cells.